The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06077760
Recruitment Status : Recruiting
First Posted : October 11, 2023
Last Update Posted : May 20, 2024
ModernaTX, Inc.
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 25, 2030
Estimated Study Completion Date : December 21, 2035